ICMR to conduct clinical trial for evaluation of COVID-19 therapy with Oxford University

By: |
July 09, 2021 10:29 PM

The trial -- 'India-UK RECOVERY (Randomised Evaluation of COVID-19 therapy)' -- will be a multi-centre, adaptive platform trial on Covid patients, ICMR said on Friday.

COVID-19 therapyAt the Indian sites, all participants aged 18 years or above will be allocated to baricitinib vs. no additional treatment. The interim trial results will be monitored by an independent Data Monitoring Committee.

The Indian Council of Medical Research (ICMR) has proposed to conduct a clinical trial for ‘randomised evaluation of COVID-19 therapy’ along with the University of Oxford and an expression of intent for participation in it has been sought from hospitals.

The trial — ‘India-UK RECOVERY (Randomised Evaluation of COVID-19 therapy)’ — will be a multi-centre, adaptive platform trial on Covid patients, ICMR said on Friday.

“ICMR, Delhi, along with the University of Oxford is proposing to conduct a multi-centre, adaptive platform trial on COVID-19 patients, titled ‘India-UK RECOVERY (Randomised Evaluation of COVID-19 therapy),” it said.

“An expression of intent is sought from institutions/hospitals with the facilities and capacity available to participate in the clinical trial which will enroll participants admitted in their hospitals.”

According to the ICMR, the intervention arm of the trial will include baricitinib and the control arm will receive local standard of care. The trial will be initiated only after obtaining requisite regulatory and ethics approvals.

“Institutions which are interested to collaborate with ICMR on undertaking this trial may express their interest by providing the details,” it said.

Informed consent has to be obtained from each patient before enrolment into the study.

The protocol of the study describes a randomised trial among patients hospitalised for COVID-19. All eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital.

At the Indian sites, all participants aged 18 years or above will be allocated to baricitinib vs. no additional treatment. The interim trial results will be monitored by an independent Data Monitoring Committee.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1In good health: Healthcare in the new normal
220,728 fresh COVID-19 cases in Kerala, 56 deaths
3Goa misses July 31 deadline to give first COVID-19 vaccine dose to all